دورية أكاديمية
أعرض في EDS

Polymeric cGAMP microparticles affect the immunogenicity of a broadly active influenza mRNA lipid nanoparticle vaccine.

التفاصيل البيبلوغرافية
العنوان: Polymeric cGAMP microparticles affect the immunogenicity of a broadly active influenza mRNA lipid nanoparticle vaccine.
المؤلفون: Hendy DA; Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA., Ma Y; Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA., Dixon TA; Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA., Murphy CT; Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA., Pena ES; Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, USA., Carlock MA; Florida Research and Innovation Center, Port Saint, Cleveland Clinic Florida, Port St. Lucie, FL, USA., Ross TM; Florida Research and Innovation Center, Port Saint, Cleveland Clinic Florida, Port St. Lucie, FL, USA; Center for Vaccines and Immunology, University of Georgia, Athens, GA, USA; Department of Infectious Diseases, University of Georgia, Athens, GA, USA., Bachelder EM; Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA., Ainslie KM; Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA; Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, USA; Department of Microbiology and Immunology, UNC School of Medicine, University of North Carolina, Chapel Hill, NC, USA., Fenton OS; Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA. Electronic address: osfenton@unc.edu.
المصدر: Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2024 Aug; Vol. 372, pp. 168-175. Date of Electronic Publication: 2024 Jun 19.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Science Publishers Country of Publication: Netherlands NLM ID: 8607908 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-4995 (Electronic) Linking ISSN: 01683659 NLM ISO Abbreviation: J Control Release Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Amsterdam : Elsevier Science Publishers, 1984-
مواضيع طبية MeSH: Influenza Vaccines*/administration & dosage , Influenza Vaccines*/immunology , Nanovaccines*/administration & dosage , Nanovaccines*/chemistry , Nucleotides, Cyclic*/administration & dosage, Animals ; Female ; Mice ; Adjuvants, Immunologic/administration & dosage ; Antibodies, Neutralizing/immunology ; Dextrans/chemistry ; Dextrans/administration & dosage ; Immunogenicity, Vaccine ; Lipids/chemistry ; Lipids/administration & dosage ; Liposomes ; Mice, Inbred BALB C ; mRNA Vaccines ; Nanoparticles/administration & dosage ; Nanoparticles/chemistry ; Orthomyxoviridae Infections/prevention & control ; Orthomyxoviridae Infections/immunology ; Polymers/chemistry ; Polymers/administration & dosage ; RNA, Messenger/administration & dosage ; RNA, Messenger/immunology
مستخلص: Influenza outbreaks are a major burden worldwide annually. While seasonal vaccines do provide protection against infection, they are limited in that they need to be updated every year to account for the constantly mutating virus. Recently, lipid nanoparticles (LNPs) encapsulating mRNA have seen major success as a vaccine platform for SARS-CoV-2. Herein, we applied LNPs to deliver an mRNA encoding a computationally optimized broadly active (COBRA) influenza immunogen. These COBRA mRNA LNPs induced a broadly active neutralizing antibody response and protection after lethal influenza challenge. To further increase the immunogenicity of the COBRA mRNA LNPs, we combined them with acetalated dextran microparticles encapsulating a STING agonist. Contrary to recent findings, the STING agonist decreased the immunogenicity of the COBRA mRNA LNPs which was likely due to a decrease in mRNA translation as shown in vitro. Overall, this work aids in future selection of adjuvants to use with mRNA LNP vaccines.
Competing Interests: Declaration of competing interest There are no conflicts to declare.
(Copyright © 2024 Elsevier B.V. All rights reserved.)
References: Int J Pharm. 2024 Mar 5;652:123836. (PMID: 38266940)
Curr Opin Virol. 2016 Apr;17:95-103. (PMID: 26927813)
J Immunol Methods. 1998 Dec 1;221(1-2):35-41. (PMID: 9894896)
Biomaterials. 2019 Jun;205:94-105. (PMID: 30909112)
AAPS J. 2023 Jan 31;25(1):22. (PMID: 36720729)
Vaccine. 2009 Oct 23;27(45):6280-3. (PMID: 19840661)
Pathogens. 2021 Oct 20;10(11):. (PMID: 34832509)
Proc Natl Acad Sci U S A. 2018 Feb 27;115(9):E2058-E2067. (PMID: 29440426)
Pharm Res. 2021 Mar;38(3):473-478. (PMID: 33660201)
Viral Immunol. 2018 Mar;31(2):174-183. (PMID: 29373086)
Clin Vaccine Immunol. 2006 Sep;13(9):981-90. (PMID: 16960108)
Mol Pharm. 2018 Nov 5;15(11):4933-4946. (PMID: 30281314)
Hum Vaccin Immunother. 2022 Dec 31;18(1):2002083. (PMID: 35130825)
J Immunol. 2021 May 1;206(9):2015-2028. (PMID: 33820855)
J Virol. 2022 Apr 13;96(7):e0165221. (PMID: 35289635)
Sci Transl Med. 2013 Aug 28;5(200):200ra114. (PMID: 23986398)
J Control Release. 2018 Nov 10;289:114-124. (PMID: 30261204)
Science. 2022 Nov 25;378(6622):899-904. (PMID: 36423275)
Immunol Cell Biol. 2016 Nov;94(10):949-954. (PMID: 27502143)
Sci Rep. 2022 Dec 8;12(1):21232. (PMID: 36481777)
Vaccines (Basel). 2021 Dec 31;10(1):. (PMID: 35062724)
J Control Release. 2018 Jan 28;270:1-13. (PMID: 29170142)
J Control Release. 2022 Jul;347:356-368. (PMID: 35569585)
J Med Virol. 2022 Jul;94(7):2939-2961. (PMID: 35229324)
J Control Release. 2018 Mar 10;273:147-159. (PMID: 29407676)
Cell Rep Med. 2022 Jul 19;3(7):100679. (PMID: 35798000)
Nat Rev Immunol. 2015 Dec;15(12):760-70. (PMID: 26603901)
Curr Opin Virol. 2013 Oct;3(5):521-30. (PMID: 23978327)
Sci Rep. 2019 Mar 5;9(1):3492. (PMID: 30837606)
Mol Ther Nucleic Acids. 2022 Nov 09;30:421-437. (PMID: 36420215)
Immunity. 2021 Dec 14;54(12):2877-2892.e7. (PMID: 34852217)
Mol Pharm. 2022 Sep 5;19(9):3125-3138. (PMID: 35913984)
J Am Chem Soc. 2008 Aug 13;130(32):10494-5. (PMID: 18630909)
Vaccine. 2011 Apr 5;29(16):3043-54. (PMID: 21320540)
Clin Microbiol Infect. 2022 Feb;28(2):163-177. (PMID: 35020589)
Commun Biol. 2023 Feb 17;6(1):188. (PMID: 36805684)
J Exp Med. 2018 Jun 4;215(6):1571-1588. (PMID: 29739835)
Acta Biomater. 2021 Sep 1;131:16-40. (PMID: 34153512)
Virus Res. 2004 Jul;103(1-2):125-32. (PMID: 15163500)
Nano Lett. 2023 Apr 12;23(7):2593-2600. (PMID: 36942873)
Vaccines (Basel). 2020 Mar 10;8(1):. (PMID: 32164372)
ACS Appl Mater Interfaces. 2012 Aug;4(8):4149-55. (PMID: 22833690)
معلومات مُعتمدة: 75N93019C00052 United States AI NIAID NIH HHS; R01 AI147497 United States AI NIAID NIH HHS
فهرسة مساهمة: Keywords: Acetalated dextran; COBRA; Infectious disease; STING
المشرفين على المادة: 0 (Adjuvants, Immunologic)
0 (Antibodies, Neutralizing)
0 (cyclic guanosine monophosphate-adenosine monophosphate)
0 (Dextrans)
0 (Influenza Vaccines)
0 (Lipid Nanoparticles)
0 (Lipids)
0 (Liposomes)
0 (mRNA Vaccines)
0 (Nanovaccines)
0 (Nucleotides, Cyclic)
0 (Polymers)
0 (RNA, Messenger)
تواريخ الأحداث: Date Created: 20240606 Date Completed: 20240727 Latest Revision: 20240802
رمز التحديث: 20240803
مُعرف محوري في PubMed: PMC11283345
DOI: 10.1016/j.jconrel.2024.06.007
PMID: 38844178
قاعدة البيانات: MEDLINE
الوصف
تدمد:1873-4995
DOI:10.1016/j.jconrel.2024.06.007